Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
Hamilton
G
G
Experimental Surgery, University Clinic, Vienna, Austria.
Zöch
G
G
Rath
T
T
Meissl
G
G
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D002056:Burns / Q000150:complications* / Q000276:immunology; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000209:etiology / Q000628:therapy*; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D010835:Phytohemagglutinins / Q000494:pharmacology; D011183:Postoperative Complications; D006377:T-Lymphocytes, Helper-Inducer / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000473:pathology; D016305:Thymopentin; D013946:Thymopoietins / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D010446:Peptide Fragments; D010835:Phytohemagglutinins; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin